RT Journal Article SR Electronic T1 Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer JF Journal of Investigative Medicine JO J Investig Med FD BMJ Publishing Group Ltd SP 1281 OP 1286 DO 10.1136/jim-2021-001806 VO 69 IS 7 A1 Hannah Elizabeth Green A1 Jorge Nieva YR 2021 UL http://hw-f5-jim.highwire.org/content/69/7/1281.abstract AB The advent of checkpoint blockade-based immunotherapy is rapidly changing the management of lung cancer. Whereas past anticancer drugs’ primary toxicity was hematologic, the newer agents have primarily autoimmune toxicity. Thus, it is no longer enough for oncology practitioners to be skilled only in hematology. They must also understand management of autoimmune conditions, leveraging the skills of the rheumatologist, endocrinologist and gastroenterologist in the process. Herein we describe the mechanism of action and toxicities associated with immune checkpoint blockade in patients with lung cancer and provide a framework for management of adverse events.